Skip to main content
SpringerLink
Log in

Principles of Complementary and Alternative Medicine for Cancer

  • Chapter
Oncology

Abstract

Complementary and alternative medicine (CAM) is a general term used to describe techniques as diverse as chiropractic and yoga, iridology and meditation, colonic irrigation and spiritual healing. As such, it resists simple definition. Most published definitions describe CAM simply as practices outside of mainstream care. A more fundamental issue concerns the difference between complementary and alternative approaches. Alternative therapies are used in place of mainstream care. Conversely, complementary therapies are used as adjuncts to mainstream care for symptom management and to enhance quality of life. This distinction is especially important in oncology, where treatment choices can be literally a matter of life and death.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zollman C, Vickers A. ABC of complementary medicine. What is complementary medicine? BMJ 1999;319(7211):693–696.

    PubMed  CAS  Google Scholar 

  2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998;280:1569–1575.

    PubMed  CAS  Google Scholar 

  3. Druss BG, Rosenheck RA. Association between use of unconventional therapies and conventional medical services. JAMA 1999;282:651–656.

    PubMed  CAS  Google Scholar 

  4. Thomas KJ, Nicholl JP, Coleman P. Use and expenditure on complementary medicine in England: a population based survey. Complementary Ther Med 2001;9:2–11.

    CAS  Google Scholar 

  5. Fisher P, Ward A. Complementary medicine in Europe. BMJ 1994;309:107–111.

    PubMed  CAS  Google Scholar 

  6. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35(2):166–173.

    PubMed  Google Scholar 

  7. Millar WJ. Use of alternative health care practitioners by Canadians. Can J Public Health 1997;88:154–158.

    PubMed  CAS  Google Scholar 

  8. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer (Phila) 1998;83(4):777–782.

    PubMed  CAS  Google Scholar 

  9. Rees RW, Feigel I, Vickers A, et al. Prevalence of complementary therapy use by women with breast cancer. a populationbased survey. Eur J Cancer 2000;36(11):1359–1364.

    PubMed  CAS  Google Scholar 

  10. Crocetti E, Crotti N, Feltrin A, et al. The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 1998;34(3):324–328.

    PubMed  CAS  Google Scholar 

  11. Miller M, Boyer MJ, Butow PN, et al. The use of unproven methods of treatment by cancer patients. Frequency, expectations and cost. Support Care Cancer 1998;6(4):337–347.

    PubMed  CAS  Google Scholar 

  12. Gray RE, Fitch M, Goel V, et al. Utilization of complementary/ alternative services by women with breast cancer. J Health Soc Policy 2003;16(4):75–84.

    PubMed  Google Scholar 

  13. Chrystal K, Allan S, Forgeson G, et al. The use of complementary/ alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. N Z Med J 2003; 16(1168):U296.

    Google Scholar 

  14. Diefenbach MA, Hamrick N, Uzzo R, et al. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol 2003;170(1):166–169.

    PubMed  Google Scholar 

  15. Yoshimura K, Ichioka K, Terada N, et al. Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institution in Japan. Int J Clin Oncol 2003;8(1):26–30.

    PubMed  Google Scholar 

  16. Jewett MA, Fleshner N, Klotz LH, et al. Radical prostatectomy as treatment for prostate cancer [comment]. CMAJ Can Med Assoc J 2003;168(1):44–45.

    Google Scholar 

  17. Kao GD, Devine P. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer (Phila) 2000;88(3):615–619.

    PubMed  CAS  Google Scholar 

  18. Richardson MA. Biopharmacologic and herbal therapies for cancer: research update from NCCAM. J Nutr 2001; 131(11):3037S.

    PubMed  CAS  Google Scholar 

  19. Specter M. The outlaw doctor. New Yorker 2001;48.

    Google Scholar 

  20. Burzynski SR, Kubove E, Burzynski B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exp Clin Res 1987;13(suppl 1):37–43.

    PubMed  Google Scholar 

  21. Buckner JC, Malkin MG, Reed E, et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin Proc 1999; 74(2):137–145.

    PubMed  CAS  Google Scholar 

  22. Creagan ET, Moertel CG, O’Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301(13):687–690.

    PubMed  CAS  Google Scholar 

  23. Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985;312(3):137–141.

    PubMed  CAS  Google Scholar 

  24. Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol 2003;88(3):434–439.

    PubMed  CAS  Google Scholar 

  25. Bahlis NJ, McCafferty-Grad J, Jordan-McMurry I, et al. Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8(12):3658–3668.

    PubMed  CAS  Google Scholar 

  26. Moertel CG, Fleming TR, Rubin J, et al. A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 1982;306(4):201–206.

    PubMed  CAS  Google Scholar 

  27. Hildenbrand GL, Hildenbrand LC, Bradford K, et al. Five-year survival rates of melanoma patients treated by diet therapy after the manner of Gerson: a retrospective review. Altern Ther Health Med 1995;1(4):29–37.

    PubMed  CAS  Google Scholar 

  28. Zollman C, Rees R. Disputes conclusions in Hildenbrand study. Altern Ther Health Med 1997;2(4):14–15.

    Google Scholar 

  29. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme treatment of adenocarcinoma of the pancreas, with nutrition and detoxification support. Nutr Cancer 1999; 33(2):117–124.

    PubMed  CAS  Google Scholar 

  30. Gellert GA, Maxwell RM, Siegel BS. Survival of breast cancer patients receiving adjunctive psychosocial support therapy: a 10-year follow-up study. J Clin Oncol 1993;11(1):66–69.

    PubMed  CAS  Google Scholar 

  31. Spiegel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989;2(8668):888–891.

    PubMed  CAS  Google Scholar 

  32. Cunningham AJ, Edmonds CV, Jenkins GP, et al. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. Psycho-Oncology 1998;7(34):508–517.

    PubMed  CAS  Google Scholar 

  33. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 2001;345(24):1719–1726.

    PubMed  CAS  Google Scholar 

  34. Sherman SJ, Boyer LV, Sibley WA. Cerebral infarction immediately after ingestion of hydrogen peroxide solution. Stroke 1994; 25(5):1065–1067.

    PubMed  CAS  Google Scholar 

  35. Meyer CT, Brand M, DeLuca VA, et al. Hydrogen peroxide colitis: a report of three patients. J Clin Gastroenterol 1981; 3(1):31–35.

    PubMed  CAS  Google Scholar 

  36. Hirschtick RE, Dyrda SE, Peterson LC. Death from an unconventional therapy for AIDS. Ann Intern Med 1994;120(8):694.

    PubMed  CAS  Google Scholar 

  37. Kaegi E. Unconventional therapies for cancer: 1. Essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. Can Med Assoc J 1998;158(7): 897–902.

    CAS  Google Scholar 

  38. Kleijnen J, Knipschild P. Mistletoe treatment for cancer. Review of controlled trials in humans. Phytomedicine 1994;1:255–260.

    Google Scholar 

  39. McNamee D. Mistletoe extract ineffective in melanoma. Lancet 1999;354:1101.

    Google Scholar 

  40. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37(1):23–31.

    PubMed  CAS  Google Scholar 

  41. Lenartz D, Dott U, Menzel J, et al. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 2000;20(3B):2073–2076.

    PubMed  CAS  Google Scholar 

  42. Hirazumi A, Furusawa E, Chou SC, et al. Anticancer activity of Morinda citrifolia (noni) on intraperitoneally implanted Lewis lung carcinoma in syngeneic mice. Proc West Pharmacol Soc 1994;37:145–146.

    PubMed  CAS  Google Scholar 

  43. Block JB, Serpick AA, Miller W, et al. Early clinical studies with lapachol (NSC-11905). Cancer Chemother Rep [2] 1974; 4(4):27–28.

    CAS  Google Scholar 

  44. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339(12):785–791.

    PubMed  CAS  Google Scholar 

  45. Hsieh T, Chen SS, Wang X, et al. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 1997;42(3):535–544.

    PubMed  CAS  Google Scholar 

  46. de la Taille A, Hayek OR, Buttyan R, et al. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 1999; 84(7):845–850.

    PubMed  Google Scholar 

  47. Tiwari RK, Geliebter J, Garikapaty VP, et al. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 1999;14(4):713–719.

    PubMed  CAS  Google Scholar 

  48. de la Taille A, Buttyan R, Hayek O, et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000;164(4):1229–1234.

    PubMed  Google Scholar 

  49. Oh WK, George DJ, Hackmann K, et al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001;57(1):122–126.

    PubMed  CAS  Google Scholar 

  50. Pfeifer BL, Pirani JF, Hamann SR, et al. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 2000;85(4):481–485.

    PubMed  CAS  Google Scholar 

  51. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18(21):3595–3603.

    PubMed  CAS  Google Scholar 

  52. Schiff JD, Ziecheck WS, Choi B. Pulmonary embolus related to PC-SPES use in a patient with PSA recurrence after radical prostatectomy. Urology 2002;59(3):444.

    PubMed  Google Scholar 

  53. Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. N Engl J Med 2001;345(16):1213–1214.

    PubMed  CAS  Google Scholar 

  54. Lock M, Loblaw DA, Choo R, et al. Disseminated intravascular coagulation and PC-SPES: a case report and literature review. Can J Urol 2001;8(4):1326–1329.

    PubMed  CAS  Google Scholar 

  55. Small EJ, Kantoff PW, Weinberg S, et al. A prospective multicenter randomized trial of the herbal supplement, PC-SPES vs. diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa.). Proc Am Soc Clin Oncol 2002;21:178a.

    Google Scholar 

  56. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31(5):261–268.

    PubMed  CAS  Google Scholar 

  57. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum. Gan To Kagaku Ryoho 1989;16(6):2241–2249.

    PubMed  CAS  Google Scholar 

  58. Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 1988;18(6):681–686.

    PubMed  CAS  Google Scholar 

  59. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 1994;343(8906): 1122–1126.

    PubMed  CAS  Google Scholar 

  60. Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995; 18(3):216–222.

    PubMed  CAS  Google Scholar 

  61. Fujimoto S, Furue H, Kimura T, et al. Clinical evaluation of schizophyllan adjuvant immunochemotherapy for patients with resectable gastric cancer—a randomized controlled trial. Jpn J Surg 1984;14(4):286–292.

    PubMed  CAS  Google Scholar 

  62. Fujimoto S, Furue H, Kimura T, et al. Clinical outcome of postoperative adjuvant immunochemotherapy with sizofiran for patients with resectable gastric cancer: a randomised controlled study. Eur J Cancer 1991;27(9):1114–1118.

    PubMed  CAS  Google Scholar 

  63. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer (Phila) 1992;70(10): 2475–2483.

    PubMed  CAS  Google Scholar 

  64. Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15(6B): 2907–2911.

    PubMed  CAS  Google Scholar 

  65. Ohno R, Yamada K, Masaoka T, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer Immunol Immunother 1984;18(3):149–154.

    PubMed  CAS  Google Scholar 

  66. Okamura K, Suzuki M, Chihara T, et al. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate. Biotherapy 1989;1(2):103–107.

    PubMed  CAS  Google Scholar 

  67. Noda K, Takeuchi S, Yajima A, et al. Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer. Jpn J Clin Oncol 1992;22(1):17–25.

    PubMed  CAS  Google Scholar 

  68. deVere White RW, Hackman RM, Soares SE, et al. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology 2002;60(4):640–644.

    PubMed  Google Scholar 

  69. Kohlmeier L, Weterings KG, Steck S, et al. Tea and cancer prevention: an evaluation of the epidemiologic literature. Nutr Cancer 1997;27(1):1–13.

    PubMed  CAS  Google Scholar 

  70. Ji BT, Chow WH, Hsing AW, et al. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997;70(3):255–258.

    PubMed  CAS  Google Scholar 

  71. Hirose M, Hoshiya T, Akagi K, et al. Effects of green tea catechins in a rat multi-organ carcinogenesis model. Carcinogenesis (Oxf) 1993;14(8):1549–1553.

    PubMed  CAS  Google Scholar 

  72. Hirose M, Takahashi S, Ogawa K, et al. Chemoprevention of heterocyclic amine-induced carcinogenesis by phenolic compounds in rats. Cancer Lett 1999;143(2):173–178.

    PubMed  CAS  Google Scholar 

  73. Yang GY, Liao J, Kim K, et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis (Oxf) 1998;19(4):611–616.

    PubMed  CAS  Google Scholar 

  74. Chen ZP, Schell JB, Ho CT, et al. Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts. Cancer Lett 1998;129(2):173–179.

    PubMed  CAS  Google Scholar 

  75. Kelloff GJ, Crowell JA, Steele VE, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130(suppl 2S):467S–471S.

    PubMed  CAS  Google Scholar 

  76. Cassileth BR, Lucarelli C. Herb Drug Interactions in Oncology. Hamilton, Ontario: Decker, 2003.

    Google Scholar 

  77. Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7(4):273–282

    PubMed  CAS  Google Scholar 

  78. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94(16):1247–1249.

    PubMed  CAS  Google Scholar 

  79. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology (Huntingt) 1011; 13(7):1003–1008.

    Google Scholar 

  80. Prasad KN, Kumar B, Yan XD, et al. Alpha-tocopheryl duccinate, the most effective form of vitamin E for adjuvant cancer treatment: a review. J Am Coll Nutr 2003;22(2):108–117.

    PubMed  CAS  Google Scholar 

  81. Somasundaram S, Edmund NA, Moore DT, et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002;62(13):3868.

    PubMed  CAS  Google Scholar 

  82. Lesperance ML, Olivotto IA, Forde N, et al. Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat 2002; 76(2):137–143.

    PubMed  CAS  Google Scholar 

  83. Smolinske SC. Dietary supplement-drug interactions. J Am Med Womens Assoc 1999;54(4):191–192, 195.

    PubMed  CAS  Google Scholar 

  84. Boyle FM. Adverse interaction of herbal medicine with breast cancer treatment. Med J Aust 1997;167(5):286.

    PubMed  CAS  Google Scholar 

  85. Ju YH, Doerge DR, Allred KF, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogendependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62(9):2474–2477.

    PubMed  CAS  Google Scholar 

  86. Liu ZP, Yu B, Huo JS, et al. Estrogenic effects of Cimicifuga racemosa (black cohosh) in mice and on estrogen receptors in MCF-7 cells. J Med Food 2001;4(3):171–178.

    PubMed  Google Scholar 

  87. Hsieh CY, Santell RC, Haslam SZ, et al. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58(17):3833–3838.

    PubMed  CAS  Google Scholar 

  88. Bodinet C, Freudenstein J. Influence of Cimicifuga racemosa on the proliferation of estrogen receptor-positive human breast cancer cells. Breast Cancer Res Treat 2002;76(1):1–10.

    PubMed  CAS  Google Scholar 

  89. Lin HL, Liu TY, Wu CW, et al. Berberine modulates expression of mdr1 gene product and the responses of digestive track cancer cells to paclitaxel. Br J Cancer 1999;81(3):416–422.

    PubMed  CAS  Google Scholar 

  90. Yokoi T, Narita M, Nagai E, et al. Inhibition of UDP-glucuronosyltransferase by aglycons of natural glucuronides in kampo medicines using SN-38 as a substrate. Jpn J Cancer Res 1995;86(10):985–989.

    PubMed  CAS  Google Scholar 

  91. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286(2):208–216.

    PubMed  CAS  Google Scholar 

  92. Sellick SM, Zaza C. Critical review of 5 nonpharmacologic strategies for managing cancer pain. Cancer Prev Control 1998; 2(1):7–14.

    PubMed  CAS  Google Scholar 

  93. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. NIH Technology Assessment Panel on Integration of Behavioral and Relaxation Approaches into the Treatment of Chronic Pain and Insomnia. JAMA 1996;276(4):313–318.

    Google Scholar 

  94. Syrjala KL, Donaldson GW, Davis MW, et al. Relaxation and imagery and cognitive-behavioral training reduce pain during cancer treatment: a controlled clinical trial. Pain 1995;63(2): 189–198.

    PubMed  CAS  Google Scholar 

  95. Linde K, Vickers A, Hondras M, et al. Systematic reviews of complementary therapies: an annotated bibliography. Part 1: Acupuncture. BMC Complement Altern Med 2001;1(1):3.

    PubMed  CAS  Google Scholar 

  96. Alimi D, Rubino C, Pichard-Leandri E, et al. Analgesic effect of auricular acupuncture for cancer pain: a randomized, blinded, controlled trial. J Clin Oncol 2003;21(22):4120–4126.

    PubMed  Google Scholar 

  97. Weinrich SP, Weinrich MC. The effect of massage on pain in cancer patients. Appl Nurs Res 1990;3(4):140–145.

    PubMed  CAS  Google Scholar 

  98. Ferrell-Torry AT, Glick OJ. The use of therapeutic massage as a nursing intervention to modify anxiety and the perception of cancer pain. Cancer Nurs 1993;16(2):93–101.

    PubMed  CAS  Google Scholar 

  99. Grealish L, Lomasney A, Whiteman B. Foot massage. A nursing intervention to modify the distressing symptoms of pain and nausea in patients hospitalized with cancer. Cancer Nurs 2000; 23(3):237–243.

    PubMed  CAS  Google Scholar 

  100. Mock V, Atkinson A, Barsevick A, et al. NCCN Practice Guidelines for Cancer-Related Fatigue. Oncology (Huntingt) 2000;14(11A):151–161.

    PubMed  CAS  Google Scholar 

  101. Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psycho-Oncology 2001; 10(6):490–502.

    PubMed  CAS  Google Scholar 

  102. Speca M, Carlson LE, Goodey E, et al. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditationbased stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 2000;62(5):613–622.

    PubMed  CAS  Google Scholar 

  103. Field T, Morrow C, Valdeon C, et al. Massage reduces anxiety in child and adolescent psychiatric patients. J Am Acad Child Adolesc Psychiatry 1992;31(1):125–131.

    PubMed  CAS  Google Scholar 

  104. Stevensen C. The psychophysiological effects of aromatherapy massage following cardiac surgery. Complement Ther Med 1994;2(1):27–35.

    Google Scholar 

  105. Fraser J, Kerr JR. Psychophysiological effects of back massage on elderly institutionalized patients. J Adv Nurs 1993; 18(2):238–245.

    PubMed  CAS  Google Scholar 

  106. Field T, Seligman S, Scafidi F, et al. Alleviating posttraumatic stress in children following Hurricane Andrew. J Appl Dev Psychol 1996;17(1):37–50.

    Google Scholar 

  107. Ahles TA, Tope DM, Pinkson B, et al. Massage therapy for patients undergoing autologous bone marrow transplantation. J Pain Symptom Manag 1999;18(3):157–163.

    CAS  Google Scholar 

  108. Cassileth BR, Vickers AJ, Magill LA. Music therapy for mood disturbance during hospitalization for autologous stem cell transplantation: a randomized controlled trial. Cancer (Phila) 2003;98(12):2723–2729.

    PubMed  Google Scholar 

  109. Redd WH, Montgomery GH, DuHamel KN. Behavioral intervention for cancer treatment side effects. JNCI Cancer Spectrum 2001;93(11):810.

    CAS  Google Scholar 

  110. Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999;88(6):1362–1369.

    PubMed  CAS  Google Scholar 

  111. Shen J, Wenger N, Glaspy J, et al. Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial. JAMA 2000;284(21):2755–2761.

    PubMed  CAS  Google Scholar 

  112. Dundee J. Acupuncture/acupressure as an antiemetic: studies of its use in postoperative vomiting, cancer chemotherapy and sickness of early pregnancy. Complement Med Res 1988; 3(1):2–14.

    Google Scholar 

  113. Roscoe JA, Morrow GR, Bushunow P, et al. Acustimulation wristbands for the relief of chemotherapy-induced nausea. Altern Ther Health Med 2002;8(4):56–63.

    PubMed  Google Scholar 

  114. Roscoe JA, Morrow GR, Hickok JT, et al. The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. J Pain Symptom Manag 2003; 26(2):731–742.

    Google Scholar 

  115. Pearl ML, Fischer M, McCauley DL, et al. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs 1999;22(4):307–311.

    PubMed  CAS  Google Scholar 

  116. Treish I, Shord S, Valgus J, et al. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving moderately-high to highly emetogenic chemotherapy. Support Care Cancer 2003;11(8):516–521.

    PubMed  Google Scholar 

  117. Dundee JW, Ghaly RG, Bill KM, et al. Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting. Br J Anaesth 1989;63(5):612–618.

    PubMed  CAS  Google Scholar 

  118. Jacobson JS, Troxel AB, Evans J, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001;19(10):2739–2745.

    PubMed  CAS  Google Scholar 

  119. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18(5):1068–1074.

    PubMed  CAS  Google Scholar 

  120. Van Patten CL, Olivotto IA, Chambers GK, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002;20(6):1449–1455.

    PubMed  Google Scholar 

  121. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998;16(2):495–500.

    PubMed  CAS  Google Scholar 

  122. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol 2002;2:199–204.

    Google Scholar 

  123. Jacknow DS, Tschann JM, Link MP, et al. Hypnosis in the prevention of chemotherapy-related nausea and vomiting in children: a prospective study. J Dev Behav Pediatr 1994;15(4): 258–264.

    PubMed  CAS  Google Scholar 

  124. Zeltzer LK, Dolgin MJ, LeBaron S, et al. A randomized, controlled study of behavioral intervention for chemotherapy distress in children with cancer. Pediatrics 1991;88(1):34–42.

    PubMed  CAS  Google Scholar 

  125. Vasterling J, Jenkins RA, Tope DM, et al. Cognitive distraction and relaxation training for the control of side effects due to cancer chemotherapy. J Behav Med 1993;16(1):65–80.

    PubMed  CAS  Google Scholar 

  126. Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982;307(24):1476–1480.

    PubMed  CAS  Google Scholar 

  127. Troesch LM, Rodehaver CB, Delaney EA, et al. The influence of guided imagery on chemotherapy-related nausea and vomiting. Oncol Nurs Forum 1993;20(8):1179–1185.

    PubMed  CAS  Google Scholar 

  128. Cotanch PH, Strom S. Progressive muscle relaxation as antiemetic therapy for cancer patients. Oncol Nurs Forum 1987;14(1):33–37.

    PubMed  CAS  Google Scholar 

  129. Holli K. Ineffectiveness of relaxation on vomiting induced by cancer chemotherapy. Eur J Cancer 1993;29(13):1915–1916.

    Google Scholar 

  130. Syrjala KL, Cummings C, Donaldson GW. Hypnosis or cognitive behavioral training for the reduction of pain and nausea during cancer treatment: a controlled clinical trial. Pain 1992; 48(2):137–146.

    PubMed  CAS  Google Scholar 

  131. Burish TG, Lyles JN. Effectiveness of relaxation training in reducing adverse reactions to cancer chemotherapy. J Behav Med 1981;4(1):65–78.

    PubMed  CAS  Google Scholar 

  132. Lyles JN, Burish TG, Krozely MG, et al. Efficacy of relaxation training and guided imagery in reducing the aversiveness of cancer chemotherapy. J Consult Clin Psychol 1982;50(4): 509–524.

    PubMed  CAS  Google Scholar 

  133. Zeltzer L, LeBaron S, Zeltzer PM. The effectiveness of behavioral intervention for reduction of nausea and vomiting in children and adolescents receiving chemotherapy. J Clin Oncol 1984;2(6):683–690.

    PubMed  CAS  Google Scholar 

  134. Burish TG, Carey MP, Krozely MG, et al. Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol 1987;55(1):42–48.

    PubMed  CAS  Google Scholar 

  135. Lerman C, Rimer B, Blumberg B, et al. Effects of coping style and relaxation on cancer chemotherapy side effects and emotional responses. Cancer Nurs 1990;13(5):308–315.

    PubMed  CAS  Google Scholar 

  136. Feldman CS, Salzberg HC. The role of imagery in the hypnotic treatment of adverse reactions to cancer therapy. J S C Med Assoc 1990;86(5):303–306.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Andrew J. Vickers PhD (Staff)

  2. Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

    Barrie Cassileth PhD (Chief and Laurance S. Rockefeller Chair in Integrative Medicine)

Authors
  1. Andrew J. Vickers PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barrie Cassileth PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Vickers, A.J., Cassileth, B. (2006). Principles of Complementary and Alternative Medicine for Cancer. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_15

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_15

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation